The Valley Desk

Clinical trial reportTargeted oncologyPublished

Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

Institution
Merck & Co.

Publication record

Type
Clinical trial report
Venue
Targeted oncology
Published
PubMed ID
42900351
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal